Takeda stock advances launch strategy after first-half results

Takeda reported first-half fiscal 2026 results on October 29, highlighting progress in new medicine launches, regulatory filings and its transformation program. In Takeda's October 29 release, the Japanese drugmaker said revenue for the six months ended September 30 rose 8.4 percent at actual exchange rates but fell 1.0 percent at constant exchange rates.

Reported operating profit increased 60.4 percent to 406.7 billion yen. Takeda attributed the rise in part to the end of amortization for VYVANSE intangible assets and lower impairment charges. Core operating profit increased 11.2 percent at actual exchange rates to 710.6 billion yen, while the constant-rate increase was 0.7 percent. Core earnings per share reached 308 yen, up 10.5 percent at actual exchange rates but down 1.2 percent at constant exchange rates.

New Medicines Drive Commercial Focus

Takeda is relying on a group of newer medicines to support growth as mature and off-patent products face pressure. ORZEYFUL, an orexin receptor agonist for narcolepsy type 1, launched in Japan and China on October 15 after approvals in the United States, Japan and China. The US commercial launch remains subject to Drug Enforcement Administration scheduling and is expected in early November.

MIMRYLO, Takeda's treatment for erythrocytosis in adults with polycythemia vera, launched in the United States in August. The company said the product's approval was supported by Phase 3 data, while its regulatory pipeline also advanced. The US Food and Drug Administration accepted zasocitinib for priority review in plaque psoriasis, and the European Medicines Agency is reviewing the application.

Takeda also reported positive late-stage oncology data for arcotatug tavatecan, formerly identified as TAK-921, in advanced gastric cancer. The company plans a Japanese regulatory filing in fiscal 2027. These developments give investors several potential growth drivers, although commercial uptake and regulatory decisions remain key execution factors.

Guidance Reflects Foreign Exchange Benefit

Takeda raised its FY2026 revenue forecast from 4.64 trillion yen to 4.7 trillion yen and lifted its core operating profit forecast from 1.16 trillion yen to 1.19 trillion yen. The reported operating profit forecast increased from 420.0 billion yen to 453.0 billion yen, while the core earnings-per-share forecast rose from 472 yen to 482 yen. The company maintained its annual dividend forecast at 204 yen per share.

Management said the revised outlook mainly reflects a foreign-exchange benefit. Chief Executive Officer Julie Kim said the next priority is to convert launch and pipeline milestones into commercial execution, while Chief Financial Officer Milano Furuta said transformation savings are being reinvested in launches and research and development.

The real-time quote of Takeda stock showed 18.50 euros on Lang & Schwarz at 09:15 CET on Wednesday, November 4, 2026.

Takeda Pharmaceutical At A Glance

• Company: Takeda Pharmaceutical Company Limited
• ISIN: US8740602052
• Ticker: TAK
• Quote: 18.50 euros on Lang & Schwarz at 09:15 CET, Wednesday, November 4, 2026
• Reporting period: First half of fiscal 2026, ended September 30, 2026
• Next stated event: Capital Markets Day on December 11, 2026, in Tokyo

Japan's Nikkei 225 provides the broader market setting for Japanese-listed companies, while Takeda's share outlook remains tied to launch execution, regulatory milestones and currency effects.

More news and analyses on Takeda stock will track the US launch timing for ORZEYFUL, the progress of zasocitinib and the strategy update scheduled for December 11.